In a phase 2a trial, itepekimab, a monoclonal antibody targeting IL‐33, reduced exacerbation rate and improved lung function in former smokers with chronic obstructive pulmonary disease.35 The gene discussed is IL33; the disease is chronic obstructive pulmonary disease.